Sanofi has discontinued amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions, citing ESTUARY phase 3 data that did not show a meaningful edge over standard of care. Full-year 2026 guidance is unaffected.
Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.
Danaher Corporation (NYSE: DHR) reported strong second-quarter 2026 financial results, generating revenue of $6.265 billion (+5.5% YoY) and non-GAAP adjusted diluted earnings per share (EPS) of $1.94 (+8.0% YoY), with both key metrics outperforming Wall Street consensus estimates. Non-GAAP core sales grew 3.0% overall and 4.5% when excluding post-pandemic respiratory testing normalizations, driven by a rebound across Life Sciences workflows and continued adoption of clinical diagnostics menus.
Novartis Q2 2026 results show a return to sales growth, with net sales up 3% to $14.4 billion on strong demand for Kisqali, Kesimpta, Scemblix, and Pluvicto, as the company reaffirmed its full-year 2026 guidance and advanced key pipeline programs including Fabhalta and Rhapsido.
Novo Nordisk has filed a federal lawsuit accusing Eli Lilly of running misleading Zepbound and Mounjaro ads that compare outdated, lower doses of Wegovy and Ozempic — omitting newer, FDA-approved higher-strength options.
The FDA has granted traditional approval to Novartis’ Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with primary IgA nephropathy. Phase III APPLAUSE-IgAN data showed a 48% slower eGFR decline versus placebo over two years.
The LIPFENDRA FDA approval makes Merck’s enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 CORALreef data showed placebo-adjusted LDL-C reductions of 56–59% at 24 weeks.
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review for non-small cell lung cancer.
This Johnson & Johnson Q2 2026 Analysis breaks down JNJ’s second-quarter results $25.3 billion in worldwide sales, raised full-year guidance, and standout performance from its oncology and immunology drug portfolio.
The European Commission has approved Merck’s Erbitux BRAF V600E mCRC combination regimen cetuximab plus encorafenib and FOLFOX as first-line therapy for metastatic colorectal cancer with the BRAF V600E mutation, based on Phase 3 BREAKWATER data showing a 51% reduction in risk of death versus standard chemotherapy.
